Search results
Axsome (AXSM) Stock Falls Despite Q4 Earnings & Revenue Beat
Zacks via Yahoo Finance· 3 months agoAxsome Therapeutics, Inc. AXSM reported an adjusted loss of 73 cents per share for the fourth...
Axsome (AXSM) Begins Dosing in Depression Study on Sunosi
Zacks via Yahoo Finance· 2 months agoAxsome (AXSM) doses the first patient in the phase III PARADIGM study evaluating Sunosi...
Axsome (AXSM) Soars on FDA Nod for Depression Drug, Auvelity
Zacks via Yahoo Finance· 2 years agoThe FDA approves Axsome's (AXSM) Auvelity extended-release tablets for the treatment of major...
Relmada Tanks After 'Paradoxical Results' Undermine Depression Drug; Axsome Surges
Investor's Business Daily· 2 years agoRelmada Therapeutics stock crashed Thursday after its depression treatment failed a final-phase...
Biotech Stock Roundup: GILD, BLUE, AXSM's Drug Approvals, FHTX Study Update & More
Zacks via Yahoo Finance· 2 years agoDrug approvals and other regulatory updates are in focus in the biotech sector. COVID-19 vaccine...
Axsome Therapeutics Stock: Bear vs. Bull
Motley Fool· 1 year agoAxsome Therapeutics (NASDAQ: AXSM) was one of last year's hottest stocks. The biotech company had reached an exciting time: the launch of its first...
2 Biotechs That Recently Soared -- Are They Buys?
Motley Fool· 2 years agoThe biotech industry is volatile. Case in point: Axsome Therapeutics (NASDAQ: AXSM) and DBV Technologies (NASDAQ: DBVT) -- two small-cap biotechs --...
2 Reasons to Buy Axsome Therapeutics, and 1 Reason to Sell
Motley Fool· 2 years agoThe bear market hasn't dragged down Axsome Therapeutics (NASDAQ: AXSM). The biotech company...
This Growth Stock Is Soaring. Is It a Buy?
Motley Fool· 2 years agoBiotech company Axsome Therapeutics (NASDAQ: AXSM) did not perform well in the first six months of 2022, partly due to regulatory troubles. Should...
Relmada (RLMD) Lead Candidate Fails Late-Stage Depression Study
Zacks via Yahoo Finance· 2 years agoRelmada's (RLMD) phase III study, evaluating REL-1017 in major depressive disorder, fails to achieve...
